Integra LifeSciences (IART) 44th Annual J.P. Morgan Healthcare Conference summary

Market Positioning and Business Overview

• Holds leading positions in neurosurgery and tissue technologies, with $1.6B in annual revenue and strong margins.

• Demonstrates leadership in a $9.1B global medtech market, serving specialized, high-value markets with essential products.

• Strong brand equity, commercial excellence, and expertise in tissue reconstruction and neurosurgery.

• Positioned to capitalize on demographic trends, technology adoption, and international expansion.

• Products address critical needs in brain surgery, trauma, burns, and hernia repair.

Strategic Transformation and Operational Focus

• Undergoing a significant, multi-year transformation to improve operational performance and consistency.

• Executing a two-horizon strategy: first, building a sustainable foundation; second, accelerating growth.

• Four strategic imperatives: best-in-class quality, supply chain reliability, growth acceleration, and innovation.

• Investments in supply chain resiliency and capacity expansion to support global demand.

• Portfolio prioritization guides capital allocation to high-growth, high-margin areas.

Financial Performance and Outlook

• Reported trailing 12-month revenue of $1.6B, with a 62.8% adjusted gross margin and 19% adjusted EBITDA margin.

• Margin expansion plan launched, targeting $25M–$30M in savings for 2026.

• Operating cash flow reached $89M for the same period.

• Guidance for 2026 expects modest revenue and earnings growth, with supply reliability and product relaunches as key drivers.

• Leverage ratio at 4.3x in Q3, with a goal to approach 2.5–3.5x by end of 2026.